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Abstract
Background: Fracture healing is orchestrated by a specific set of events that culminates in the repair of bone and
reachievement of its biomechanical properties. The aim of our work was to study the sequence of gene expression events
involved in inflammation and bone remodeling occurring in the early phases of callus formation in osteoporotic patients.
Methodology/Principal Findings: Fifty-six patients submitted to hip replacement surgery after a low-energy hip fracture
were enrolled in this study. The patients were grouped according to the time interval between fracture and surgery: bone
collected within 3 days after fracture (n = 13); between the 4th and 7th day (n = 33); and after one week from the fracture
(n = 10). Inflammation- and bone metabolism-related genes were assessed at the fracture site. The expression of pro-
inflammatory cytokines was increased in the first days after fracture. The genes responsible for bone formation and
resorption were upregulated one week after fracture. The increase in RANKL expression occurred just before that, between
the 4th–7th days after fracture. Sclerostin expression diminished during the first days after fracture.
Conclusions: The expression of inflammation-related genes, especially IL-6, is highest at the very first days after fracture but
from day 4 onwards there is a shift towards bone remodeling genes, suggesting that the inflammatory phase triggers bone
healing. We propose that an initial inflammatory stimulus and a decrease in sclerostin-related effects are the key components
in fracture healing. In osteoporotic patients, cellular machinery seems to adequately react to the inflammatory stimulus,
therefore local promotion of these events might constitute a promising medical intervention to accelerate fracture healing.
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Introduction
The management of fragility fractures associated with osteopo-
rosis is difficult due to several factors including inadequate fixation
strength of implants used to stabilize the fracture until union of
bone occurs. In particular, the fragility fractures affecting the
metaphyseal region of long bones are associated with an increased
rate of complications. Several studies report nonunion in 2–10%,
malalignment after surgery in 4–40%, metal work failure in 1–
10%, and reoperation in 3–23% [1]. Experimental studies have
shown that the decline in the capacity for fracture repair is age
related. Disturbance of the full redevelopment of mechanical
strength within fracture calluses in elderly animals has been shown
in experimental rat models. In the human being it is possible that
fracture healing is affected by aging [2], particularly in the elderly
osteoporotic patients [3]. In another study it was described that in
6, 26 and 52 weeks old rats, there is upon aging a delay in
radiographic progression of fracture healing but the expression of
the key genes involved in this process is not age-dependent [1,4,5].
The fracture healing response and its temporal gene expression in
elderly patients with osteoporosis has not been adequately
investigated at the cellular and molecular level. Identification of
the mechanisms that lead to fracture healing disturbances in
patients with osteoporosis is of outstanding importance because
they could allow prevention and better management of these
healing complications. In addition, the biological processes behind
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fracture healing in osteoporosis might hold the key for future
medical interventions.
Fracture healing recapitulates certain aspects of skeletal devel-
opment and growth, involving interplay of cells, growth factors and
extracellular matrix. Following injury, a blood clot is formed in the
fracture site [6,7]. This hematoma is the source of several signaling
molecules that induce an inflammatory cascade of events that
initiate healing [8,9]. Based on histological observations of healing
fractures, bone repair was defined in animal models by an initial
inflammatory phase (lasting for about three days), a catabolic phase
where damaged tissues are removed, and an anabolic phase where
new bone is rebuilt. Within several days of the initial inflammatory
response there is a sequence of events that results in the formation of
new bone through the development of a structure named callus.
Experimental studies have related temporal gene expression with
bone healing. In a study with Sprague-Dawley rats, gene expression
was evaluated on days 3 and 11 post-fracture. The authors showed
that different molecular pathways of gene expression regulate
different phases of bone healing [10].
This work aims to study the profile of genes involved in
inflammation and bone remodeling during the 3 major steps of the
early phase of callus formation in human bone after a hip fragility
fracture.
Results
Study population
Fifty-six patients 8067 years of age, 75% of female gender,
which suffered a hip fragility fracture, were enrolled in this study.
There were no statistical significant differences in age and gender
between the 3 study groups (Table 1): those who had surgery less
than three days after fracture (group 1), between four and seven
days (group 2) and eight or more days post-fracture (group 3).
Inflammation and growth factors genes
The local expression of nine genes related to the inflammatory
phase of bone healing (IL-1b, IL-6, TNF, BMP2, BMP4, TGF-b1,
IGF-I, FGF-2 and PDGF-b) was analyzed (Figure 1, Table 2). IL-
1b, IL-6 and TNF are cytokines that have an important role in
potentiating the inflammatory cascade. Concordantly, the expres-
sion of these genes was highest during the first 3 post-fracture days
and decreases thereafter. Specifically, IL6 had a higher expression
in group 1 than in group 2 (p-value = 0.021) and IL1B, although
expressed at low levels, remained stable, decreasing slightly after
the 4th–7th day post-fracture (p-value = 0.087). On the contrary,
TNF expression was stable, showing only a slight tendency to
decrease over time (p-value = 0.208).
BMPs are a set of growth factors and cytokines belonging to the
TGF-b superfamily and are involved in the creation of bone tissue
architecture. In fracture healing, BMP-2 and BMP-4 play
important roles in osteoblast differentiation. Accordingly, it was
observed that the expression levels of BMP2 were highest until 3
days post-fracture and decreased thereafter (p-value = 0.023),
while BMP4 expression remained fairly constant in all groups (p-
value = 0.852). TGFB exhibited a constant negative slope between
the three groups (p-value = 0.051).
IGF-I is a hormone involved in bone matrix synthesis and there
were no differences in its expression levels in the three groups
analyzed (p-value = 0.817). The growth factors FGF-2 and PDGF-
b are involved in the formation of new blood vessels. Their
expression tended to decrease slightly from group 1 to group 2 and
was clearly decreased after 8 days post-fracture (FGF2: p-
value = 0.091 and PDGFb: p-value = 0.043).
Overall, these findings suggest that the expression levels of
inflammatory genes and growth factors are particularly high
during the three first days post-fracture and decrease from the day
4 onwards.
Osteoprotegerin, RANK and RANKL
OPG is a negative regulator of bone resorption and, as
expected, its expression was slightly lower in group 3 than in
group 1 (p-value = 0.168) (Figure 2A, Table 2). On the other hand,
RANK produced by osteoclast precursors showed a tendency to
increase over time (p-value = 0.072). Finally, RANKL expressed by
osteoblasts, stromal cells and immune system cells had its highest
level at days 4 to 7 post-fracture (group 2) and decreased thereafter
(p-value = 0.267).
The ratio RANKL/OPG regulates the balance between
remodeling and formation. In this study, the ratio RANKL/OPG
mRNA peaked in group 2 and tended to decrease later on (p-
value = 0.078).
Steoblast-related genes
The expression of three genes that play important functions in
the osteoblast and its activity was studied (Figure 2B, Table 2).
Core-binding factor, alfa subunit 1/runt-related transcription
factor 2 (CBFA1/RUNX2) and osterix (OSX) are transcription
factors that play a crucial role in osteoblast differentiation, and
ALP is an enzyme expressed at a later stage being involved in bone
matrix maintenance. In our results, CBFA1/RUNX2 expression
was slightly higher in group 2 than in group 1 and then remained
constant and was similar in groups 2 to 3 (p-value = 0.521). On the
other hand, OSX expression levels were similar in groups 1 and 2
and marginally higher in group 3 (p-value = 0.149). Regarding
ALP, levels were slightly lower in group 2 as compared to group 1
but were similar between groups 2 and 3 (p-value = 0.726).
Osteocyte-related genes
Sclerostin (SOST) is produced by the osteocyte and regulates
negatively osteoblast differentiation by inhibiting Wnt/b-catenin
Table 1. Description of the study population divided between the event of fracture and surgery.
Group 1 Group 2 Group 3 p-value
Until 3 days post-fracture 4 to 7 days post-fracture 8 or more days post-fracture
Number of patients 13 33 10
Age (years) 8065 7967 8367 0.326
Female gender (%) 85 79 50 0.121
Values represent mean6standard deviation.
Comparisons between groups performed with ANOVA or chi-square tests.
doi:10.1371/journal.pone.0016947.t001
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signaling. In this work we found a highly significant reduction in
SOST levels overtime (p-value = 0.001) (Figure 2C, Table 2).
Osteoclast-related genes
Four genes that regulate osteoclast differentiation and function
were studied (Figure 2D, Table 2). Tartrate-resistant acid
phosphatase (TRAP) is an enzyme expressed by pre-osteoclasts
and active osteoclasts; on the other hand, cathepsin K (CTSK), b3
subunit of the avb3 integrin (ITGB3) and ATPase H+ transporter
(ATP6V0D2) are proteins involved in the process of bone
resorption.
We observed a marked increase in TRAP and a more modest
change in CTSK and ATP6V0D2 expression over the post fracture
period (TRAP: p-value = 0.009; CTSK: p-value = 0.027 and
ATP6V0D2: p-value = 0.076). On the other hand, the expression
of ITGB3 remained constant (p-value = 0.658).
Discussion
Although some studies have addressed the sequence of events in
fracture healing, the research was mainly based on histological
examination of healthy individual’s tissue and on molecular studies
in animal models. Based on these previous histological and
molecular studies of healing fractures the initial stages of these
process have been proposed to include an early inflammatory and
unspecific anabolic phase (first 24 hours up to third day),
immediately followed by a non specific catabolic phase (up to
the end of the first week) that sets the conditions for a more bone
specific anabolic phase (first week and thereafter) [10,11,12,13,14].
Thus, in our study, patients were grouped into these three phases
according to the time between fracture and surgery and the main
objective was to address the gene expression variations during
early callus formation in patients that have suffered a hip fragility
fracture. We showed that many inflammation-related genes have
higher levels of expression until 3 days post-trauma while genes
related to osteoblast and osteoclast activity increase at day 4 and
thereafter.
Cytokine gene expression (IL1B, IL6 and TNF) was more
pronounced during the first days after fracture, as described in
younger individuals. Specifically, the decrease in IL6 expression
levels was far more pronounced than what was observed with the
other pro-inflammatory cytokines evaluated. Of interest, reports
state that IL1B is upregulated in response to the fracture event but
in IL1B knockout mice there was no change in callus formation
and bone and cartilage matrix production [15]. On the other
hand, in the absence of TNF signaling there was a 2–4 days delay
in chondrogenic differentiation and a 2–3 weeks delay in
endochondral tissue resorption [16]. Regarding IL-6, studies in
knockout mice have shown that there was a delay in callus
formation and lower osteoclast density [17]. Therefore, in
accordance with our results, IL-6 appears to have a pivotal role
in the early phase of fracture healing, probably through the
increase in the pro-osteoclastogenic stimuli. Moreover, expression
levels of TGFB, BMP2, BMP4, PDGFB and FGF2 was highest
during the first 3 days post-fracture. The variation encountered in
these elderly fragility fracture patients is similar to the findings
obtained in animal models studies [8] and in healthy younger
subjects [18] where the inflammatory phase occurs before day 3
post-fracture, being IL-6 a crucial player in this early phase of
fracture healing.
Regarding the RANK-RANKL-OPG system, OPG expression
diminished gradually after fracture, releasing the inhibitory signal
for osteoclast differentiation. Concordantly, RANKL peaks at 4th–
7th day after trauma, creating a stimulus for osteoclast differen-
Figure 1. Relative expression of inflammation and growth factors genes grouped according to the time between the event of
fracture and the surgery. Each gene was normalized to the expression of the housekeeping genes B2M and PMM1. *p-value,0.05 for comparisons
between the three groups. (Points represent median values). IL1B – interleukin-1b; IL6 – interleukin-6; TNF – tumor necrosis factor; IGF1 – insulin
growth factor-1 ; FGF2 – fibroblast growth factor 2 ; PDGFB – platelet derived growth factor b; BMP – Bone morphogenetic protein; TGFB1 –
transforming growth factor b1.
doi:10.1371/journal.pone.0016947.g001
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tiation from its precursors. Therefore, the ratio RANKL/OPG was
high during days 4–7 post-fracture, not only due to an increase in
RANKL but also to a decrease in OPG expression switching the
balance to a pro-resorptive status, as described in a young mouse
model [9].
Concerning osteoblast differentiation and activity, it was
observed that CBFA1/RUNX2 and OSX, two regulatory factors
essential for its differentiation [19], had a weak increase indicating
the beginning of an initial osteogenic phase. CBFA1/RUNX2
increases from the initial phase of bone healing whereas OSX
increases after 4 days post-fracture sustaining the evidence that
OSX acts later than CBFA1/RUNX2 in osteoblast lineage
commitment [20]. On the other hand, ALP, a marker for
osteoblast activity, decreases from early stages of bone healing.
Table 2. Comparison between the relative gene expression levels of patients submitted to hip replacement surgery due to low-
energy fracture in relation to the days between fracture and surgery.
Fragility fracture patients p-value*
Until 3 days post-fracture 4–7 days post-fracture 8 or more days post-fracture
IL1B 0.111
(0.07–0.30)
0.101
(0.03–0.16)
0.039
(0.02–0.11)
0.087
IL6 2.596
(0.94–5.23)
0.643
(0.24–2.46)
0.348
(0.08–0.90)
0.021
TNF 0.236
(0.20–0.63)
0.238
(0.09–0.43)
0.102
(0.08–0.56)
0.208
TGFB1 0.759
(0.28–0.94)
0.507
(0.25–0.83)
0.244
(0.17–0.49)
0.051
BMP2 0.443
(0.20–1.32)
0.344
(0.09–0.55)
0.114
(0.03–0.41)
0.023
BMP4 2.406
(1.16–6.66)
2.372
(0.72–5.54)
2.516
(0.86–3.26)
0.852
IGFI 0.341
(0.13–2.24)
0.280
(0.16–0.80)
0.365
(0.27–0.66)
0.817
FGF2 0.354
(0.25–1.08)
0.292
(0.12–0.85)
0.168
(0.10–0.36)
0.091
PDGFB 0.738
(0.30–1.71)
0.520
(0.19–0.82)
0.203
(0.08–0.58)
0.043
OPG 3.340
(1.63–4.56)
1.938
(0.99–4.18)
0.979
(0.85–2.09)
0.168
RANKL 13.803
(5.46–22.36)
25.838
(8.11–39.20)
15.305
(3.86–32.70)
0.267
RANK 0.095
(0.06–0.37)
0.290
(0.14–0.52)
0.438
(0.24–0.86)
0.072
RANKL/OPG 4.887
(2.71–7.78)
11.362
(5.32–22.28)
5.581
(3.08–23.08)
0.078
CBFA1/RUNX2 1.954
(1.08–2.63)
2.574
(1.31–4.02)
2.178
(1.12–2.58)
0.521
OSX 0.629
(0.28–1.86)
0.655
(0.24–0.87)
0.888
(0.68–2.71)
0.149
ALP 5.393
(2.53–7.86)
4.407
(2.47–5.95)
4.054
(2.64–10.05)
0.726
SOST 1.402
(1.07–3.66)
0.668
(0.39–1.18)
0.274
(0.19–0.77)
0.001
TRAP 4.204
(1.31–11.46)
9.660
(3.78–24.41)
22.758
(9.18–83.48)
0.009
CTSK 30.276
(8.72–132.81)
63.593
(15.67–250.62)
151.91
(87.71–558.88)
0.027
ITGB3 2.045
(1.43–2.97)
1.619
(1.16–2.79)
1.292
(0.82–2.48)
0.658
ATP6V0D2 4.898
(2.78–10.71)
9.839
(4.51–25.20)
32.378
(7.65–68.59)
0.076
Values represent median (Q1–Q3).
Comparisons between the 3 groups performed with Kruskall-Wallis H test.
*p-value for comparison between the 3 groups.
IL1B – interleukin-1b; IL6 – interleukin-6; TNF – tumor necrosis factor; TGFB1 – transforming growth factor b1; BMP – Bone morphogenetic protein; IGF1 – insulin growth
factor-1; FGF2 – fibroblast growth factor 2; PDGFB – platelet derived growth factor b; OPG – osteoprotegerin; RANK – receptor activator of nuclear factor kB; RANKL –
RANK ligand; CBFA1/RUNX2 – core binding factor a1/runt-related transcription factor 2; OSX – osterix; ALP – alkaline phosphatase; SOST – sclerostin; TRAP – tartrate-
resistant acid phosphatase; CTSK – cathepsin K; ITGB3 – subunit b3 of the integrin avb3; ATP - ATPase H+ transporter.
doi:10.1371/journal.pone.0016947.t002
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This gene expression profile had been already observed in other
studies [18,21,22] and it is not entirely surprising, since this
enzyme is involved in bone matrix production and our study is
focused on the early changes related to fracture, in a stage where
the formation of new bone matrix is still not occurring.
Sclerostin is a protein produced by the osteocyte that inhibits
canonical Wnt/b-catenin signaling, thus blocking osteoblast
proliferation and differentiation. The contribution of this pathway
to fracture healing depends on the function of b-catenin in
different stages of fracture repair, namely in the commitment and
regulation of osteoblasts [23]. Only one study in young mice has
addressed the levels of expression of sclerostin during fracture
repair and they found that this protein was downregulated during
the process [24]. In fact, our results, the first obtained in fragility
fracture patients, showed that SOST expression decreases signif-
icantly from the beginning of the healing cascade, suggesting that
there is an initial blockage of osteoblast proliferation and
differentiation that is subsequently released over the period of
fracture healing.
The role of the osteoclast in bone healing is somewhat
controversial. Bone formation overcomes the loss of continuity
and osteoclasts seem to play a role at a later phase, in the
remodeling stage. Moreover, in a longitudinal study where the
serum levels of biochemical markers associated with bone
metabolism were assessed, the authors showed that the markers
for bone resorption remained elevated up to four months after
fracture [21]. At gene expression level, we found that the
osteoclast-specific genes TRAP, CTSK and ATP6V0D2 were
significantly increased from day 8 onward after fracture, pointing
to an activation of osteoclast function. In fact, the RANKL/OPG
ratio is highest in group 2, whereas the CTSK values are increased
in group 3, indicating that during 4–7 days after fracture,
osteoclastogenesis stimulus was ongoing intensively whereas at
day 8 and later osteoclasts containing cathepsin K had already
been formed in relatively high numbers. The active role of
osteoclast during the early phase of fracture healing was already
described in sheep where it was proposed that these cells not only
resorb bone but adjust the system, together with osteoblasts, in
order to improve bone strength [25].
Due to the fact that we are dealing with human subjects, the
study had to have a cross-sectional design. Thus, it is not possible
to rule out the intrinsic variability of different individuals.
However, the statistical significance for many of the changes
described seems to refute this. Besides, the RNA used was
extracted from the site of fracture (trabecular bone) that not only
has the bone cells that we are interested in, but also other cell
types, such as adipocytes, bone marrow cells and cells infiltrating
the tissues during the initial healing phase. However, the bone
remodeling genes studied are relatively specific for bone cells and it
is unlikely that this technical aspect represent a relevant
confounding factor in our study.
Taken together, our results indicate that in patients with hip
fragility fractures, the expression of inflammation-related genes is
highest during the first days after fracture but from day 4 onwards
there is a shift towards bone cell remodeling genes, suggesting that
the machinery of bone healing is conserved in osteoporotic bone.
Figure 2. Relative expression of bone metabolism-related genes divided according to the time between the event of fracture and
the surgery. RANK, RANKL and OPG (A), osteoblast (B), osteocyte (C) and osteoclast-specific genes (D) were studied in the three study groups. Each
gene was normalized to the expression of the housekeeping genes B2M and PMM1. *p-value,0.05 for comparisons between the three groups.
(Points represent median values). RANK – receptor activator of nuclear factor kB; RANKL – RANK ligand; OPG – osteoprotegerin; CBFA1/RUNX2 – core
binding factor a1/runt-related transcription factor 2; OSX – osterix; ALP – alkaline phosphatase; SOST – sclerostin; ITGB3 – subunit b3 of the integrin
avb3; TRAP – tartrate-resistant acid phosphatase; ATP - ATPase H+ transporter; CTSK – cathepsin K.
doi:10.1371/journal.pone.0016947.g002
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In addition, the changes observed in IL-6 expression profile
suggest that this pro-inflammatory cytokine plays a pivotal role in
triggering the healing cascade. Moreover, sclerostin expression is
quickly reduced after fracture and we hypothesize that this allows
osteoblasts to escape from its inhibitory effect, thus promoting the
expression of bone formation genes. Interestingly, RANKL
expression is subsequently increased, generating the stimulus for
osteoclast activity, as confirmed also by the later rise in the
expression of the bone resorption-related genes. Our findings
bring new insights for clarifying bone fracture healing process in
osteoporotic patients. We propose that an initial inflammatory
stimulus and a decrease in sclerostin-related effects are key events
for an adequate fracture healing. Thus, in osteoporotic patients,
locally promoting these events might provide promising medical
interventions for accelerating fracture healing and reduce the rate
of complications.
Methods
Sample collection
Patients that suffered a low-energy hip fracture and underwent
total hip replacement surgery at the Orthopedic Department of
Hospital de Santa Maria were consecutively recruited for this
study from 2007 until 2009. Epidemiological and clinical data such
as age, gender and days between the fracture and surgery were
collected. Patients with other metabolic bone diseases and with
bone metastases were excluded.
Written informed consent was obtained from all patients and
the study was conducted in accordance with the ethical principles
for medical research involving human subjects expressed in the
Declaration of Helsinki, as amended in Edinburgh (2000), and was
approved by Santa Maia Hospital Ethics Committee.
According to the time between fracture and surgery, patients
were divided in three groups: those who had hip replacement
surgery between zero and three days after fracture (group 1), four
and seven days after fracture (group 2) or eight or more days after
fracture (group 3).
After the medical procedure, the femoral epiphyses were snap-
frozen at 280uC.
RNA extraction
Without defrosting the bone specimen, small trabecular bone
pieces were collected from the site of fracture and pulverized using
a mortar and pestle. RNA was then extracted using TRIzol
reagent (Invitrogen, UK) with proteinase K (Bioline, UK)
digestion [26] to better dissolve the dense extracellular matrix.
The procedure used was a modified version of the protocol
described by Ireland [27]. Briefly, 80mg of bone powder was placed
in TRIzol reagent and homogenized. Lipids were solubilized with
0.2 volumes of chloroform and the fraction containing RNA was
preserved. Proteinase K digestion (3.3mg proteinase K/mg bone)
was performed at 55uC. RNAwas precipitated with 1 volume of ice-
cold isopropyl alcohol. RNA pellet was dissolved in RNase/DNase-
free water. As this method leaves residual chemical contaminants,
RNA was cleaned using a commercial kit (RNeasy mini kit, Qiagen,
Germany) and genomic DNA contaminants were removed by
Table 3. Real time PCR primer sequences of the genes
studied.
Gene
GenBank
number Primer sequences
B2M NM_004048 F: CTATCCAGCGTACGCCAAAGATTC
R: CTTGCTGAAAGACAAGTCTGAATG
PMM1 NM_002676 F: GAATGGCATGCTGAACATCT
R: TCCCGGATCTTCTCTTTCTTG
IL1B NM_000576 F: TACCTGTCCTGCGTGTTGAA
R: TCTTTGGGTAATTTTTGGGATCT
IL6 NM_000600 F: GATGAGTACAAAAGTCCTGATCCA
R: GATGAGTACAAAAGTCCTGATCCA
TNF NM_000594 F: CAGCCTCTTCTCCTTCCTGAT
R: GCCAGAGGGCTGATTAGAGA
TGFB1 NM_000660 F: GCAGCACGTGGAGCTGTA
R: CAGCCGGTTGCTGAGGTA
BMP2 NM_001200 F: CGGACTGCGGTCTCCTAA
R: GGAAGCAGCAACGCTAGAAG
BMP4 NM_001202 F: CTGCAACCGTTCAGAGGTC
R: TGCTCGGGATGGCACTAC
FGF2 NM_002006 F: TTCTTCCTGCGCATCCAC
R: TTCTGCTTGAAGTTGTAGCTTGAT
PDGFB NM_002608 F: CTGGCATGCAAGTGTGAGAC
R: CGAATGGTCACCCGAGTTT
IGFI NM_001111283 F: TGTGGAGACAGGGGCTTTTA
R: ATCCACGATGCCTGTCTGA
CBFA1/RUNX2 NM_004348 F: CGGAATGCCTCTGCTGTTA
R: TCTGTCTGTGCCTTCTGGGT
OSX NM_152860 F: CATCTGCCTGGCTCCTTG
R: CAGGGGACTGGAGCCATA
ALP NM_000478 F: AGAACCCCAAAGGCTTCTTC
R: CTTGGCTTTTCCTTCATGGT
TRAP NM_001111034 F: CGGCCACGATCACAATCT
R: GCTTTGAGGGGTCCATGA
ITGB3 NM_000212 F: GGGCAGTGTCATGTTGGTAG
R: CAGCCCCAAAGAGGGATAAT
CTSK NM_000396 F: GCCAGACAACAGATTTCCATC
R: CAGAGCAAAGCTCACCACAG
ATP6V0D2 NM_152565 F: CATTCTTGAGTTTGAGGCCG
R: CCGTAATGATCCGCTACGTT
SOST NM_025237 F: AGACCAAAGACGTGTCCGAG
R: GGGATGCAGCGGAAGTC
RANK NM_003839 F: GAACATCATGGGACAGAGAAATC
R: GGCAAGTAAACATGGGGTTC
RANKL NM_003701 F: AGAGAAAGCGATGGTGGATG
R: TATGGGAACCAGATGGGATG
OPG NM_002546 F: CGCTCGTGTTTCTGGACAT
R: GTAGTGGTCAGGGCAAGGG
B2M – b2-microglobulin; PMM1 - phosphomannomutase 1; IL1B – interleukin-
1b; IL6 – interleukin-6; TNF – tumor necrosis factor; TGFB1 – transforming
growth factor b1; BMP – Bone morphogenetic protein; IGF1 – insulin growth
factor-1; FGF2 – fibroblast growth factor 2; PDGFB – platelet derived growth
factor b; OPG – osteoprotegerin; RANK – receptor activator of nuclear factor kB;
RANKL – RANK ligand; CBFA1/RUNX2 – core binding factor a1/runt-related
transcription factor 2; OSX – osterix; ALP – alkaline phosphatase; SOST –
sclerostin; TRAP – tartrate-resistant acid phosphatase; CTSK – cathepsin K; ITGB3
– subunit b3 of the integrin avb3; ATP - ATPase H+ transporter.
doi:10.1371/journal.pone.0016947.t003
Table 3. Cont.
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DNaseI treatment (Qiagen, Germany). RNA concentration was
determined spectrophotometrically (Nanodrop ND-1000 Spectro-
photometer, Thermo Fisher Scientific, USA) and its integrity was
assessed by lab-on-a-chip technology (Agilent RNA 6000 Nano Kit,
Agilent technologies, USA) according to the manufacturer’s
instructions. RNA was stored at 280uC until further use.
Quantitative reverse transcription-polymerase chain
reaction (PCR)
Reverse transcription cDNA synthesis was performed on 60ng
of RNA from each sample using the DyNAmo cDNA synthesis kit
(Finnzymes, Finland) and 300ng of random hexamer primers
according to the manufacturer’s instructions.
Each cDNA template (3ng/ml) was amplified in duplicate with
DyNAmo Flash SYBR green qPCR kit (Finnzymes, Finland) on a
Rotor-Gene thermocycler (Qiagen, Germany) according to the
manufacturer’s instructions. Reactions were incubated at 50uC for
2 minutes and at 95uC for 7 minutes, followed by denaturation at
95uC for 10 seconds and annealing/extension at 60uC for
10 seconds. The reactions were validated by the presence of a
single peak in the melt curve analysis.
Primers for the housekeeping and target genes (Table 3) were
designed using the software Probefinder (http://qpcr.probefinder.
com, Roche, Switzerland) in order to anneal in separate exons
preventing amplification of contaminating genomic DNA.
Real time PCR results were analyzed using the standard curve
analysis. The cycle threshold (CT) is defined as the number of
cycles required for the fluorescent signal to cross the threshold and
exceed the background level. The efficiency of the PCR should be
100%, meaning that for each cycle the amount of product doubles.
A good reaction should have an efficiency of 90–100%, which
corresponds to a slope between 23.58 and 23.10. The conversion
of the CT value in relative expression levels was performed with
the slope and the Y intersect extracted from the standard curve
and applying the equation 10(Y intersect-CT/slope) [28,29]. The values
obtained were normalized with the housekeeping genes b-2-
microglobulin (B2M) and phosphomannomutase 1 (PMM1).
Statistical analysis
To define the exposure variable, patients were divided, according
to the number of days between the event of fracture and the surgery,
in three groups. The distributions of continuous variables were
compared between groups using either analysis of variance
(ANOVA), for normally-distributed characteristics, or Kruskal-
Wallis H test, for distributions with significant deviation from
normality (according to Shapiro-Wilk test). For nominal variables,
chi-squared test was used. Significance level was set at 0.05.
Statistical analysis was performed using the Statistical Package
for Social Sciences manager software, version 17.0 (SPSS, Inc,
Chicago, IL, USA).
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